Endo International plc
endo.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 10-K, filed Mar 6, 2024. Its latest SEC filing is a SCHEDULE 13G from Feb 14, 2025.
10-K for FY2023, filed Mar 6, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells branded and generic medicines, including sterile injectables, to wholesalers, retailers and healthcare providers.
10-K for FY2023, filed Mar 6, 2024For branded products, which we sell primarily through our Branded Pharmaceuticals and Sterile Injectables segments, we seek to invest in…View ↗
Generic products are the pharmaceutical and therapeutic equivalents of branded products and are generally sold under their generic…View ↗
The Sterile Injectables segment includes a product portfolio of approximately 40 product families, including branded sterile injectable…View ↗
We primarily sell our products to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order…View ↗
How Did They Make Money?
Branded Pharmaceuticals is the largest segment; customers order products and generally pay after delivery.
10-K for FY2023, filed Mar 6, 2024
-
10-K for FY2023, filed Mar 6, 2024
FY2023 revenue by reportable segment ↗
$2B
-
10-K for FY2023, filed Mar 7, 2024
$2B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Branded Pharmaceuticals
Sold outright
10-K for FY2023, filed Mar 6, 2024 |
43%
FY2020: 27%
|
Branded Pharmaceuticals, FY2023
$859.1M Sources
|
Sold outright |
|
Sterile Injectables
Sold outright
10-K for FY2023, filed Mar 6, 2024 |
21%
FY2020: 43%
|
Sterile Injectables, FY2023
$429.6M Sources
|
Sold outright |
|
Generic Pharmaceuticals
Sold outright
10-K for FY2023, filed Mar 6, 2024 |
32%
FY2020: 27%
|
Generic Pharmaceuticals, FY2023
$650.4M Sources
|
Sold outright |
|
International Pharmaceuticals
Sold outright
|
3.6%
FY2020: 3.4%
|
International Pharmaceuticals, FY2023
$72.5M Sources
|
Sold outright |
Who Were Their Customers?
Endo sells to wholesalers and distributors, retail chains, and healthcare organizations and government agencies; wholesalers and distributors then supply pharmacies, hospitals, clinics and care facilities.
10-K for FY2023, filed Mar 6, 2024We primarily sell our products to wholesalers, retail drug store chains, supermarket chains, mass merchandisers, distributors, mail order…View ↗
10-K for FY2023, filed Mar 6, 2024
2023 2022 2021 Cencora, Inc., previously known as AmerisourceBergen Corporation (1) 29 % 35 % 36 % McKesson Corporation 25 % 26 % 32 %…View ↗
Did Revenues Turn Into Profits?
Not on paper. It lost $2.4B in FY2023, but brought in more cash than it spent: $340.8M of free cash flow.
10-K for FY2023, filed Mar 7, 2024
$381.9MView ↗
10-K for FY2023, filed Mar 7, 2024
−$2.4BView ↗
10-K for FY2023, filed Mar 7, 2024
$340.8MView ↗
How Were They Changing?
-
Apr 18, 2024
Endo agreed to sell substantially all of its assets
The agreement follows confirmation of the Chapter 11 plan; closing remains subject to conditions and approvals.
Sources
8-K, filed Apr 18, 2024
Consummation of the transactions contemplated by the Purchase Agreement is subject to certain conditions set forth in the Purchase…View ↗
-
Mar 25, 2024
Bankruptcy court confirmed Endo’s reorganization plan
Sources
8-K, filed Mar 25, 2024
On March 22, 2024, the Bankruptcy Court entered an order confirming and approving the fourth amended version of the Plan, which was filed…View ↗
Shrank. Revenue fell 31% in 4 years, from $2.9B in FY2019 to $2B in FY2023, about 9% a year.
QWO discontinued
The older report planned a QWO launch for cellulite treatment; the latest report says production and sales ceased.
10-K for FY2020, filed Feb 26, 2021 10-K for FY2023, filed Mar 6, 2024Branded Pharmaceuticals: Accelerating performance of organic growth drivers in our Specialty Products portfolio, expanding margin in our…View ↗
This portfolio has also included QWO® (collagenase clostridium histolyticum-aaes), an injectable treatment for moderate to severe cellulite…View ↗
Loading...
